Morpholino

MO1-phgdh

ID
ZDB-MRPHLNO-240723-1
Name
MO1-phgdh
Previous Names
None
Target
Sequence
5' - GCCATTATTATCGTGGACTTGCGGA - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-phgdh
No data available
Phenotype
Phenotype resulting from MO1-phgdh
Phenotype of all Fish created by or utilizing MO1-phgdh
Phenotype Fish Conditions Figures
cranial nerve VI decreased object quality, abnormal rw0Tg + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
cranial nerve X physical object quality, ameliorated rw0Tg + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
cranial nerve VII decreased object quality, abnormal rw0Tg + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
cranial nerve V physical object quality, ameliorated rw0Tg + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
cranial nerve X decreased object quality, abnormal rw0Tg + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
hindbrain morphology, abnormal rw0Tg + MO1-phgdh standard conditions Fig. 5 from Hathazi et al., 2021
cranial nerve VII physical object quality, ameliorated rw0Tg + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
cranial nerve VI physical object quality, ameliorated rw0Tg + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
cranial nerve V decreased object quality, abnormal rw0Tg + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
whole organism phgdh expression decreased amount, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5 from Hathazi et al., 2021
neuromuscular junction development process quality, ameliorated slc24a5b1/b1 + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
neuromuscular junction development process quality, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
skeletal muscle cell morphology, ameliorated slc24a5b1/b1 + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
somite shape, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5 from Hathazi et al., 2021
whole organism L-serine decreased amount, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5 from Hathazi et al., 2021
vertical myoseptum synapse assembly disrupted, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
vertical myoseptum synapse assembly occurrence, ameliorated slc24a5b1/b1 + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
skeletal muscle cell morphology, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
post-vent region increased curvature, abnormal slc24a5b1/b1 + MO1-phgdh standard conditions Fig. 5Fig. 6 from Hathazi et al., 2021
post-vent region curvature, ameliorated slc24a5b1/b1 + MO1-phgdh chemical treatment by environment: L-serine Fig. 6 from Hathazi et al., 2021
Citations